Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 15/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28263995 | 1.00 | HDAC4 (0.52) | HDAC4HDAC1CPB2FOLH1EPHX1 | |
| SCHEMBL16915092 | 0.90 | HDAC4 (0.44) | HDAC4HDAC1CPB2FOLH1 | |
| SCHEMBL16915094 | 0.90 | HDAC4 (0.44) | HDAC4HDAC1CPB2FOLH1 | |
| SCHEMBL16915024 | 0.88 | CPB2 (0.43) | HDAC4HDAC1CPB2FOLH1 | |
| SCHEMBL16915025 | 0.88 | CPB2 (0.43) | HDAC4HDAC1CPB2FOLH1 | |
| SCHEMBL2805502 | 0.85 | HDAC4 (0.52) | HDAC4HDAC1CPB2EPHX1 | |
| SCHEMBL2805504 | 0.85 | HDAC4 (0.52) | HDAC4HDAC1CPB2EPHX1 | |
| SCHEMBL27780890 | 0.84 | HDAC4 (0.54) | HDAC4HDAC1EPHX1 | |
| SCHEMBL22777304 | 0.84 | EPHX1 (0.51) | HDAC4HDAC1EPHX1 | |
| Hydrochloric Acid SCHEMBL4446986 | 0.83 | HDAC4 (0.53) | HDAC4HDAC1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4526336-A1 | NOVEL RECOMBINANT FIBRINOGEN VARIANTS FOR FIBRIN SEALANTS FOR SURGICAL WOUND CARE | Julius-Maximilians-Universität Würzburg (DE) | 2025-03-26 | — | — | EP | claimed |
| CN-118256603-A | Modified enzymes | 牛津纳米孔科技公开有限公司 | 2024-06-28 | — | — | CN | claimed |
| WO-2023222770-A1 | Novel recombinant fibrinogen variants for fibrin sealants for surgical wound care | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2023-11-23 | — | — | WO | claimed |
| US-20230212535-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-07-06 | — | — | US | claimed |
| EP-4198125-A2 | PIF1-LIKE HELICASE AND USE THEREOF | Qitan Technology Ltd., Beijing (CN) | 2023-06-21 | — | — | EP | claimed |
| US-11525125-B2 | Modified helicases | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-12-13 | — | — | US | claimed |
| EP-4063382-A9 | PIF1-LIKE HELICASE AND APPLICATION THEREOF | Qitan Technology Ltd., Beijing (CN) | 2022-11-16 | — | — | EP | claimed |
| US-20210009971-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2021-01-14 | — | — | US | claimed |
| EP-3575410-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2019-12-04 | — | — | EP | claimed |
| US-20180037874-A9 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2018-02-08 | — | — | US | claimed |
| US-20160257942-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2016-09-08 | — | — | US | claimed |
| EP-3058088-A2 | MODIFIED ENZYMES | Oxford Nanopore Technologies Limited (GB) | 2016-08-24 | — | — | EP | claimed |
| US-20150191709-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-07-09 | — | — | US | claimed |
| EP-2875128-A1 | MODIFIED HELICASES | Oxford Nanopore Technologies Limited (GB) | 2015-05-27 | — | — | EP | claimed |
| WO-2015055981-A2 | MODIFIED ENZYMES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-04-23 | — | — | WO | claimed |
| WO-2014013260-A1 | MODIFIED HELICASES | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2014-01-23 | — | — | WO | claimed |
| US-20260001937-A1 | NOVEL RECOMBINANT FIBRINOGEN VARIANTS FOR FIBRIN SEALANTS FOR SURGICAL WOUND CARE | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2026-01-01 | — | — | US | disclosed |
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | Wang, Jieyi (US) | 2025-12-25 | — | — | US | disclosed |
| EP-2212422-A1 | METHODS AND COMPOSITIONS | Medical Research Council (GB) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009056803-A1 | METHODS AND COMPOSITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | TNFRSF9, FCGR3B, FCGR2A | HDAC4 3653/4885HDAC1 3518/4885CPB2 3275/4885 |
| US-20260001937-A1 | NOVEL RECOMBINANT FIBRINOGEN VARIANTS FOR FIBRIN SEALANTS FOR SURGICAL WOUND CARE | FGB, F7, F11 | HDAC4 4772/4885HDAC1 4209/4885CPB2 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.